Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma
Gastroenterol Hepatol (N Y)
.
2024 Feb;20(2):119-122.
Author
Robin Kate Kelley
1
Affiliation
1
Professor of Clinical Medicine Division of Hematology/Oncology Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, California.
PMID:
38414909
PMCID:
PMC10895911
No abstract available